Viral hepatitis is a major public health threat and a leading cause of death worldwide. Annual mortality from viral hepatitis is similar to that of other major infectious diseases such as HIV and tuberculosis. Highly effective prevention measures and treatments have made the global elimination of viral hepatitis a realistic goal, endorsed by all WHO member states. Ambitious targets call for a global reduction in hepatitis-related mortality of 65% and a 90% reduction in new infections by 2030. This Commission draws together a wide range of expertise to appraise the current global situation and to identify priorities globally, regionally, and nationally needed to accelerate progress. We identify 20 heavily burdened countries that account for over 75% of the global burden of viral hepatitis. Key recommendations include a greater focus on national progress towards elimination with support given, if necessary, through innovative financing measures to ensure elimination programmes are fully funded by 2020. In addition to further measures to improve access to vaccination and treatment, greater attention needs to be paid to access to affordable, high-quality diagnostics if testing is to reach the levels needed to achieve elimination goals. Simplified, decentralised models of care removing requirements for specialised prescribing will be required to reach those in need, together with sustained efforts to tackle stigma and discrimination. We identify key examples of the progress that has already been made in many countries throughout the world, demonstrating that sustained and coordinated efforts can be successful in achieving the WHO elimination goals.
基金:
BRC of Imperial College NHS Trust; NIHR Research Professorship; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MR/R015600/1, MR/R011117/1, MR/P025064/1, MR/L002086/1] Funding Source: UKRI; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA048063] Funding Source: NIH RePORTER
第一作者单位:[1]Imperial Coll London, Div Surg & Canc, London, England[*1]Imperial Coll London, Div Infect Dis, London, England
通讯作者:
通讯机构:[1]Imperial Coll London, Div Surg & Canc, London, England[*1]Imperial Coll London, Div Infect Dis, London, England
推荐引用方式(GB/T 7714):
Cooke Graham S.,Andrieux-Meyer Isabelle,Applegate Tanya L.,et al.Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission[J].LANCET GASTROENTEROLOGY & HEPATOLOGY.2019,4(2):135-184.doi:10.1016/S2468-1253(18)30270-X.
APA:
Cooke, Graham S.,Andrieux-Meyer, Isabelle,Applegate, Tanya L.,Atun, Rifat,Burry, Jessica R....&Yau, Johnny.(2019).Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission.LANCET GASTROENTEROLOGY & HEPATOLOGY,4,(2)
MLA:
Cooke, Graham S.,et al."Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission".LANCET GASTROENTEROLOGY & HEPATOLOGY 4..2(2019):135-184